4.7 Article

G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells

期刊

CLINICAL IMMUNOLOGY
卷 143, 期 1, 页码 83-87

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2012.01.011

关键词

Myeloid-derived suppressor cells; T-cell alloreactivity; Allogeneic hematopoietic; stem cell transplantation; G-CSF

资金

  1. Institute for the Promotion of Innovation by Science and Technology in Flander
  2. Flanders National Fund for Scientific Research

向作者/读者索取更多资源

The role of myeloid-derived suppressor cells (MDSC) is emerging in transplantation. An expansion of myeloid progenitor cells with suppressive capacity has been reported to occur as a bystander phenomenon in the course of allogeneic hematopoietic stem cell transplantation (alto-HSCT) protocols, particularly, in mice during bone marrow chimerism induction and in human stem cell donors during G-CSF-mobilization protocols. Hypothesizing that such 'regulatory myeloid cells' play a role in regulating post-transplant T-cell alloreactivity, we performed a phenotypical and functional characterization of these cells in peripheral blood stem cell grafts of G-CSF-treated donors. We demonstrate that expanding myeloid cells in the peripheral blood of G-CSF-mobilized donors comprise the typical phenotype of the mononuclear and polymorphonuclear MDSC-subtypes that were recently described in cancer patients, and that both MDSC-subsets have the capacity to regulate alloreactive T-cell responses in-vitro. This study provides the basis for investigating the clinical relevance of MDSC and MDSC-subtypes in human allo-HSCT. (C) 2012 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pharmacology & Pharmacy

Imaging and therapeutic targeting of the tumor immune microenvironment with biologics

Sana Arnouk, Timo W. M. De Groof, Jo A. Van Ginderachter

Summary: The presence and activity of tumor-infiltrating immune cells, such as activated CD8+ T cells and macrophages, play a crucial role in tumor progression and therapy response. Understanding the immune infiltrate in tumors is important for predicting prognosis, optimizing therapeutic success, and monitoring treatment outcomes.

ADVANCED DRUG DELIVERY REVIEWS (2022)

Article Biochemical Research Methods

Single-cell RNA and protein profiling of immune cells from the mouse brain and its border tissues

Isabelle Scheyltjens, Hannah Van Hove, Karen De Vlaminck, Daliya Kancheva, Jonathan Bastos, Monica Vara-Perez, Ana Rita Pombo Antunes, Liesbet Martens, Charlotte L. Scott, Jo A. Van Ginderachter, Yvan Saeys, Martin Guilliams, Niels Vandamme, Kiavash Movahedi

Summary: This protocol provides a detailed workflow for single-cell multi-omic analysis of the mouse brain immune compartment. It includes steps for brain dissection, cell dissociation, high-dimensional flow cytometry, droplet-based single-cell RNA sequencing, and analysis of the data. This optimized workflow allows for a comprehensive assessment of immune cell heterogeneity and activation in the brain, which is crucial for studying neurological disorders.

NATURE PROTOCOLS (2022)

Article Hematology

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Marta Sobas, Jean-Jacques Kiladjian, Yan Beauverd, Natalia Curto-Garcia, Parvis Sadjadian, Lee Yung Shih, Timothy Devos, Dorota Krochmalczyk, Serena Galli, Maria Bieniaszewska, Ilona Seferynska, Mary Frances McMullin, Anna Armatys, Adrianna Spalek, Joanna Waclaw, Mihnea Zdrenghea, Laurence Legros, Francois Girodon, Krzysztof Lewandowski, Anna Angona Figueras, Jan Samuelsson, Aitor Abuin Blanco, Pascale Cony-Makhoul, Angela Collins, Chloe James, Rajko Kusec, Marie Lauermannova, Maria Sol Noya, Malgorzata Skowronek, Lukasz Szukalski, Anna Szmigielska-Kaplon, Marielle Wondergem, Iryna Dudchenko, Joanna Gora Tybor, Kamel Laribi, Anna Kulikowska de Nalecz, Jean-Loup Demory, Katell Le Du, Sonja Zweegman, Carlos Besses Raebel, Radek Skoda, Stephane Giraudier, Martin Griesshammer, Claire N. Harrison, Jean-Christophe Ianotto

Summary: In this study of young MPN patients, high rates of thrombotic events and disease transformation were observed. JAK2V617F mutation and hyperviscosity symptoms were identified as risk factors, with splenomegaly potentially being a new risk factor for transformation in essential thrombocythemia. Conventional risk scores were not able to predict survival for young ET or polycythemia vera patients.

BLOOD ADVANCES (2022)

Article Medicine, Research & Experimental

Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting

Marco Erreni, Francesca D'Autilia, Roberta Avigni, Evangelia Bolli, Sana M. Arnouk, Kiavash Movahedi, Pieterjan Debie, Achille Anselmo, Raffaella Parente, Cecile Vincke, Fijs W. B. van Leeuwen, Paola Allavena, Cecilia Garlanda, Alberto Mantovani, Andrea Doni, Sophie Hernot, Jo A. Van Ginderachter

Summary: Nanobodies (Nbs) have been identified as an elegant alternative to conventional monoclonal antibodies for cancer therapy, but there is a lack of detailed microscopic insight into the in vivo pharmacokinetics of different Nb formats in tumor-bearers, especially for the targeting of pro-tumoral tumor-associated macrophages (TAMs) located in less penetrable tumor regions.

THERANOSTICS (2023)

Review Oncology

Hallmarks of Cancer Affected by the MIF Cytokine Family

Romina Mora Barthelmess, Benoit Stijlemans, Jo A. Van Ginderachter

Summary: The aim of this review is to summarize the available information regarding the MIF family in cancer. MIF and DDT are both highly expressed in cancer patients and their functions are related to 9 out of 10 hallmarks of cancer, indicating their potential as therapeutic targets. New diagnostic methods and treatments have decreased the mortality rates of cancer patients, but further improvements are warranted based on the identification of novel tumor-promoting molecules.

CANCERS (2023)

Article Hematology

Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria

Hubert Schrezenmeier, Austin Kulasekararaj, Lindsay Mitchell, Regis Peffault de Latour, Timothy Devos, Shinichiro Okamoto, Richard Wells, Evan Popoff, Antoinette Cheung, Alice Wang, Ioannis Tomazos, Yogesh Patel, Jong Wook Lee

Summary: This study identifies LDH levels as an important determinant of fatigue and quality of life outcomes in patients with PNH.

ANNALS OF HEMATOLOGY (2023)

Article Hematology

Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case-control study in the International PNH Registry

Britta Hoechsmann, Regis Peffault de Latour, Anita Hill, Alexander Roeth, Timothy Devos, Christopher J. Patriquin, Wen-Chien Chou, Deepak Jain, Ke Zu, Chuntao Wu, Jong Wook Lee

Summary: The objective of this analysis was to identify risk factors for thromboembolic events (TE) in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were not treated with C5 inhibitors. Multivariable analysis revealed that a history of TE, >= 30% GPI-negative granulocytes, and LDH ratio >= 1.5 x ULN with >= 2 high disease activity criteria are risk factors for TE in PNH patients.

ANNALS OF HEMATOLOGY (2023)

Article Hematology

Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study

Alexandre Theocharides, Heinz Gisslinger, Valerio De Stefano, Vincenzo Accurso, Alessandra Iurlo, Timothy Devos, Miklos Egyed, Eric Lippert, Regina Garcia Delgado, Nathan Cantoni, Anders E. A. Dahm, Damianos Sotiropoulos, Erik Houtsma, Aoife Smyth, Amir Iqbal, Paola Di Matteo, Mike Zuurman, Peter A. W. te Boekhorst

Summary: This study demonstrates that ruxolitinib treatment in patients with polycythemia vera who are resistant and/or intolerant to hydroxyurea maintains durable hematocrit control, reduces the need for phlebotomies, and is generally well tolerated.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

Review Immunology

A few good reasons to use nanobodies for cancer treatment

Neema Ahishakiye Jumapili, Maida Zivalj, Romina Mora Barthelmess, Geert Raes, Timo W. M. De Groof, Nick Devoogdt, Benoit Stijlemans, Cecile Vincke, Jo A. Van Ginderachter

Summary: mAbs have limitations in their distribution and penetration in tumor microenvironment, as well as their ability to reach the brain. Nanobodies, being smaller in size, possess superior abilities in tumor penetration and infiltration into brain tumors. However, the rapid clearance of nanobodies from circulation may affect their suitability for therapy, although their noncovalent binding to albumin can help increase their serum half-life.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Review Pharmacology & Pharmacy

Current status and future expectations of nanobodies in oncology trials

Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W. M. De Groof, Nick Devoogdt

Summary: Monoclonal antibodies have played a significant role in personalized medicine for cancer, but their size and complexity may hinder certain cancer diagnosis and therapy applications. Nanobodies, with their unique structure and pharmacological features, have shown promising potential as complementary tools for cancer diagnostics and therapeutics. This overview provides insights into nanobody-based diagnostics and therapeutics that have been tested in clinical trials and highlights upcoming preclinical developments.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)

Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, Denis Schallier, Sandrine Aspeslagh, Ilse Vaneycken, Geert Raes, Jo A. Van Ginderachter, Tony Lahoutte, Vicky Caveliers, Marleen Keyaerts

Summary: Macrophages play a vital role in the body, and anti-inflammatory macrophages targeting CD206 are involved in various diseases. This study evaluated the safety and biodistribution of a PET tracer targeting CD206 in human subjects, and found that the tracer was safe, rapidly cleared from the blood, and enabled high contrast imaging at 90 minutes after injection. Preliminary results showed higher tumor uptake in patients with disease progression.

JOURNAL OF NUCLEAR MEDICINE (2023)

Article Immunology

Flt3L therapy increases the abundance of Treg-promoting CCR7(+) cDCs in preclinical cancer models

Emile J. Clappaert, Daliya Kancheva, Jan Brughmans, Ayla Debraekeleer, Pauline M. R. Bardet, Yvon Elkrim, Dagmar Lacroix, Maida Zivalj, Ahmed E. I. Hamouda, Jo A. Van Ginderachter, Sofie Deschoemaeker, Damya Laoui

Summary: This study found that while Flt3L treatment can increase all cDC subsets in the tumor, it does not reduce tumor growth in any of the models. In addition, in some cases, Flt3L treatment also leads to an increase in CD81(+)migcDC1 subset, which has Treg-inducing potential. Overall, increasing cDC numbers in the tumor alone may not improve anti-tumor responses and may not be beneficial for cancer treatment.

FRONTIERS IN IMMUNOLOGY (2023)

Review Oncology

Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy

Maida Zivalj, Jo A. Van Ginderachter, Benoit Stijlemans

Summary: The aim of this review is to summarize the available information regarding Lipocalin-2 in tumor progression. Lipocalin-2 expression is correlated with tumorigenesis and can be considered as a biomarker and potential drug target in cancer therapy.

CANCERS (2023)

Article Pharmacology & Pharmacy

Self-Immolative Nanobody-Cysteine Residue Modification for Controlled Immunodrug Delivery

Maximilian Scherger, Yannick A. A. Pilger, Judith Stickdorn, Patric Komforth, Sascha Schmitt, Sana M. M. Arnouk, Els Lebegge, Kaloian Koynov, Hans-Joachim Rader, Jo A. A. Van Ginderachter, Lutz Nuhn

Summary: In this study, a procedure is demonstrated for site-specific reversible bioconjugation of genetically engineered single domain antibodies, called nanobodies, using self-immolative linkers (SILs). The flow cytometry and microscopy images confirm cellular uptake and biological affinity of the modified nanobodies. This strategy can be extended to other therapeutically relevant representatives of nanobodies, highlighting the versatility of this reversible reductive-responsive bioconjugation in a broad field of applications.

ADVANCED THERAPEUTICS (2023)

Article Hematology

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis

Timothy Devos, Dominik Selleslag, Nikki Granacher, Violaine Havelange, Fleur Samantha Benghiat

Summary: This article provides recommendations for the use of ruxolitinib in Belgian myelofibrosis patients, including dose optimization/monitoring, adverse events, and interruption/rechallenge management.

HEMATOLOGY (2022)

暂无数据